Results 321 to 330 of about 5,889,184 (390)

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

Advanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source

Clinical value and molecular role of PRDXs family in prostate cancer. [PDF]

Front Oncol
Yao Y, Zheng Q, Qian C, Gu P, Zhang M, Zhang Z.   +5 more
europepmc   +1 more source

Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF‐1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression

Advanced Science, EarlyView.
Cancer cells drive adjacent adipose tissue to release fatty acids by secreting CCL2, which activates PPARα‐dependent lipolysis. The resulting fatty acid influx amplifies HIF‐1α/CCL2 signaling, establishing a positive feedback loop that fuels tumor growth.
Jeong‐Eun Yun, Jieun Seo, Jiwon Koh, Seock‐Ah Im, Ki Yong Hong, Yeseon Son, Do‐Won Jeong, Junji Fukuda, Jong‐Wan Park, Yang‐Sook Chun   +9 more
wiley   +1 more source

Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T. [PDF]

Prostate Cancer
Shore ND, Antonarakis ES, Hafron J, Moses KA, Pieczonka C, Lowentritt B, Sheikh N, George DJ, Dorff TB.   +8 more
europepmc   +1 more source

Magnesium Structure‐Function Integration Platform for Spatiotemporal Multi‐Modality Therapy: Combining Hormonotherapy and Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
The schematic illustration of the MHSCG platform for spatiotemporal responsive GRb1 release to induce androgen deprivation therapy (ADT) and immunogenic cell death (ICD) multimodal therapy in prostate cancer. Abstract Metal‐based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited
Rui Zan, Qianping Mao, Keyi Wang, Guodong Zou, Shi Yang, Hua Qiu, Xiang Fang, Guiqing Wang, Xinyi Zhou, Jiexia Wen, Shuai Jiang, Ran Huang, Qiuming Peng, Tao Suo   +13 more
wiley   +1 more source

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. [PDF]

EBioMedicine
Portman N, Mak B, Yeung N, Lin HM, Kim RMN, Mellor R, Ardolino L, Gutierrez D, Raneri M, Scheinberg T, Handelsman DJ, Moujaber T, Meikle PJ, Huynh K, Joshua AM, Hoy AJ, Butler L, Horvath LG.   +17 more
europepmc   +1 more source

Osmotic Tension Asymmetry Drives Electrotactic Migration via PDLIM7‐Polarized Microfilament Coordination in Breast Cancer Cells

Advanced Science, EarlyView.
This study establishes an electric field‐induced directional migration model using fluorescence tension probes to visualize microfilament forces and intracellular osmotic pressure dynamics in the electrotactic migration of breast cancer cells. This model delineates how electromechanical interactions among membrane potential, ion channels, OP, traction ...
Ling Zhu, Zihui Zheng, Wang Li, Chenyi Shou, Ying Zhao, Lijun Zhang, Xiaoli Shi, Yunfeng Hu, Huanhuan Zhao, Huiwen Wu, Jun Guo   +10 more
wiley   +1 more source

Advances in prostate cancer treatment with moderate and ultra-hypofractionated radiotherapy. [PDF]

World J Clin Oncol
Meng LL, Di YP, Ma L, Qu BL.
europepmc   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Experience of uncertainty in prostate cancer: A qualitative study. [PDF]

PLoS One
Li Y, Gillanders D, Finucane A.
europepmc   +1 more source